2020
DOI: 10.1038/s41598-020-59089-x
|View full text |Cite
|
Sign up to set email alerts
|

Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma

Abstract: We evaluated prognostic factors of adult low-grade glioma (LGG) according to the new 2016 WHO classification. Records of 153 patients diagnosed with WHO grade II LGG between 2003 and 2015 were retrospectively reviewed. Based on the 2016 WHO classification, 80 patients (52.3%) had diffuse astrocytoma, IDH-mutant; 45 (29.4%) had oligodendroglioma, IDH-mutant and 1p/19q-codeleted (ODG); and 28 (18.3%) had diffuse astrocytoma, IDH-wildtype. Gross total resection (GTR) was performed in 71 patients (46.4%), subtotal… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
27
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 52 publications
(31 citation statements)
references
References 26 publications
4
27
0
Order By: Relevance
“…Numerous studies have recently demonstrated that the maximal safe extent of tumoral resection (EOR) is the first-line treatment resulting in better survival [ 21 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ]. In the last decade, the qualitative and subjective descriptions of EOR as “gross total resection”, “near total resection”, and “subtotal resection”, are being replaced by precise and objective estimation based on the volume of residual tumor according to the following formula: “EOR = preoperative tumor volume − postoperative tumor volume/preoperative tumor volume” [ 21 , 66 ].…”
Section: Role Of Surgerymentioning
confidence: 99%
See 1 more Smart Citation
“…Numerous studies have recently demonstrated that the maximal safe extent of tumoral resection (EOR) is the first-line treatment resulting in better survival [ 21 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ]. In the last decade, the qualitative and subjective descriptions of EOR as “gross total resection”, “near total resection”, and “subtotal resection”, are being replaced by precise and objective estimation based on the volume of residual tumor according to the following formula: “EOR = preoperative tumor volume − postoperative tumor volume/preoperative tumor volume” [ 21 , 66 ].…”
Section: Role Of Surgerymentioning
confidence: 99%
“…Although the maximal safe resection remains the key element in the treatment of LGG, there is still no general consensus in literature regarding a minimum EOR cut-off value related to an effective survival benefit. Furthermore, the impact of the new 2016 WHO molecular subtypes, among the EOR classes, is still poorly investigated and the optimal postoperative treatment remains disputed, especially when a radical resection is not functionally possible [ 65 , 69 ]. Recently, Kavouridis et al [ 69 ] demonstrated that the prognosis is influenced by minimal volumetric differences among the different molecular classes.…”
Section: Role Of Surgerymentioning
confidence: 99%
“…Today, personalized medicine approaches according to molecular and epigenetic tumor data tailor adjuvant treatment for patients with lower grade gliomas [2,3]. With refinements in therapy and improvements in life expectancy, [4][5][6] the perception of glioma gradually shifts from a lethal to a chronic disease, with median survival times ranging between 5 and 15 years [6][7][8][9]. Therefore, effects of therapeutic interventions on patients' quality of life have gained interest in recent years [10,11].…”
Section: Electronic Supplementary Materialsmentioning
confidence: 99%
“…According to histological characteristics, gliomas can be classi ed into grades -based on World Health Organization (WHO) criteria published in 2007 and 2016 [2,3]. Oligodendroglial tumor, a subtype of lowgrade glioma (LGG), belongs to WHO grade (oligodendroglioma) or (anaplastic oligodendroglioma) [4].Despite advances in various therapeutic strategies, such as surgery, chemotherapy, radiotherapy, immunotherapy and biologics, the prognosis and outcomes remain poor in patients suffering from oligodendroglial tumor [5]. Therefore, the identi cation of e cient pathological biomarkers and therapeutic targets is urgent.…”
Section: Introductionmentioning
confidence: 99%